Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours

被引:69
作者
Jaenne, Pasi A. [1 ]
机构
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
关键词
non-small cell lung cancer; acquired resistance; irreversible tyrosine kinase inhibitors; allelic dilution; epidermal growth factor receptor; T790M mutation; MET amplification;
D O I
10.1016/S0169-5002(08)70099-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For patients with advanced non-small cell lung cancer (NSCLC), the introduction of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, into clinical practice was promising. Treatment with either of these agents is associated with an objective response in 10-20% of patients. Subsequent studies have shown that patients responsive to gefitinib/erlotinib have tumours containing somatic activating mutations in the EGFR gene. Although impressive clinical and radiological responses have been observed in these patients, tumour progression occurs after the prolonged administration of gefitinib/erlotinib as acquired resistance develops. In order to combat acquired resistance, research has been largely focused on determining the factors underlying it. Two resistance mechanisms have so far been identified: a secondary mutation in the EGFR gene, T790M, and amplification of the MET proto-oncogene. This review wilt centre on T790M, which is thought to cause steric hindrance and impair the binding of gefitinib/erlotinib. A novel class of irreversible TKIs currently under development may retain activity against some common resistance mechanisms, including T790M. The next challenge is to identify accurately the subgroup of patients with NSCLC whose tumours harbour EGFR T790M. To this end, post-treatment tumour specimens will. be needed to establish molecular profiles for each patient. In addition, novel, highly sensitive technology wilt be required to detect these mutations. This is because allelic dilution, whereby the EGFR gene is amplified but only a few copies of the T790M allele are needed to confer resistance, may obscure results of conventional sequencing methods. The importance of identifying patients who harbour T790M cannot be overstated; the development of irreversible TKIs wilt have profound implications for their treatment. In this way, treatment strategies in NSCLC are becoming increasingly tailored to the individual, and may set an example for other areas of oncology. (C) 2008 Elsevier Ireland Ltd. Ali rights reserved.
引用
收藏
页码:S3 / S9
页数:7
相关论文
共 42 条
[1]   Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].
Balak, Marissa N. ;
Gong, Yixuan ;
Riely, Gregory J. ;
Somwar, Romel ;
Li, Allan R. ;
Zakowski, Maureen F. ;
Chiang, Anne ;
Yang, Guangli ;
Ouerfelli, Ouathek ;
Kris, Mark G. ;
Ladanyi, Marc ;
Miller, Vincent A. ;
Pao, William .
CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501
[2]   MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].
Bean, James ;
Brennan, Cameron ;
Shih, Jin-Yuan ;
Riely, Gregory ;
Viale, Agnes ;
Wang, Lu ;
Chitale, Dhananjay ;
Motoi, Noriko ;
Szoke, Janos ;
Broderick, Stephen ;
Balak, Marissa ;
Chang, Wen-Cheng ;
Yu, Chong-Jen ;
Gazdar, Adi ;
Pass, Harvey ;
Rusch, Valerie ;
Gerald, William ;
Huang, Shiu-Feng ;
Yang, Pan-Chyr ;
Miller, Vincent ;
Ladany, Marc ;
Yang, Chih-Hsin ;
Pao, William .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937
[3]  
Brabender J, 2001, CLIN CANCER RES, V7, P1850
[4]   Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].
Cappuzzo, F ;
Hirsch, FR ;
Rossi, E ;
Bartolini, S ;
Ceresoli, GL ;
Bemis, L ;
Haney, J ;
Witta, S ;
Danenberg, K ;
Domenichini, I ;
Ludovini, V ;
Magrini, E ;
Gregorc, V ;
Doglioni, C ;
Sidoni, A ;
Tonato, M ;
Franklin, WA ;
Crino, L ;
Bunn, PA ;
Varella-Garcia, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655
[5]   Strategies to overcome resistance to targeted protein kinase inhibitors [J].
Daub, H ;
Specht, K ;
Ullrich, A .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) :1001-1010
[6]   ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines [J].
Engelman, JA ;
Jänne, PA ;
Mermel, C ;
Pearlberg, J ;
Mukohara, T ;
Fleet, C ;
Cichowski, K ;
Johnson, BE ;
Cantley, LC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3788-3793
[7]   MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Mitsudomi, Tetsuya ;
Song, Youngchul ;
Hyland, Courtney ;
Park, Joon Oh ;
Lindeman, Neal ;
Gale, Christopher-Michael ;
Zhao, Xiaojun ;
Christensen, James ;
Kosaka, Takayuki ;
Holmes, Alison J. ;
Rogers, Andrew M. ;
Cappuzzo, Federico ;
Mok, Tony ;
Lee, Charles ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
SCIENCE, 2007, 316 (5827) :1039-1043
[8]   Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer [J].
Engelman, Jeffrey A. ;
Mukohara, Toru ;
Zejnullahu, Kreshnik ;
Lifshits, Eugene ;
Borras, Ana M. ;
Gale, Christopher-Michael ;
Naumov, George N. ;
Yeap, Beow Y. ;
Jarrell, Emily ;
Sun, Jason ;
Tracy, Sean ;
Zhao, Xiaojun ;
Heymach, John V. ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (10) :2695-2706
[9]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[10]   EGFR inhibitors: what have we learned from the treatment of lung cancer? [J].
Giaccone, G ;
Rodriguez, JA .
NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (11) :554-561